T/SRMA 19-2023 Active Group standards

T/SRMA 19-2023 The general requirements for ApoE polymorphism testing in individuals at risk of Alzheimer's disease

Publish Date: 2023-05-23 Implement Date: 2023-06-01 For services related to genuine standard inquiry, procurement, translation, and other related services in China, please Contact Us

Price: $ 20.00

Out of stock

Basic Information

Standard Code: T/SRMA 19-2023

Standard Type: Group standards

Standard Status: Active

is_force_gb: no

CCS Name: Medicine, health, and labor protection

ICS Name: Laboratory medicine

Publish Date: 2023-05-23

Implement Date: 2023-06-01

Scope

Scope: This document specifies the technical requirements for ApoE gene typing detection. This document is applicable to all medical institutions that conduct ApoE gene polymorphism detection on human samples, and is intended for reports related to the diagnosis, treatment, prevention, and non-pharmacological therapy of Alzheimer's disease (AD). Main technical content: This document stipulates the technical requirements for ApoE gene typing detection and proposes recommendations for personalized non-pharmacological treatment of Alzheimer's disease (AD). The main provisions include: - ApoE gene typing: Clarifies the correlation between the ApoE gene and Alzheimer's disease and the distribution of ApoE gene polymorphisms. - Requirements for ApoE gene typing detection: Specifies specific requirements from aspects such as sample collection and processing, and ApoE gene typing detection methods. - Several recommendations for non-pharmacological treatment of Alzheimer's disease: Proposes non-pharmacological treatment recommendations for AD from aspects such as lifestyle intervention, cognitive intervention, multi-modal intervention, exercise training, and other therapies.